195 related articles for article (PubMed ID: 25247397)
21. CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia.
Hoehn D; Medeiros LJ; Chen SS; Tian T; Jorgensen JL; Ahmed Y; Lin P
Am J Clin Pathol; 2012 Feb; 137(2):213-9. PubMed ID: 22261446
[TBL] [Abstract][Full Text] [Related]
22. Immunophenotypic profile predictive of KIT activating mutations in AML1-ETO leukemia.
De J; Zanjani R; Hibbard M; Davis BH
Am J Clin Pathol; 2007 Oct; 128(4):550-7. PubMed ID: 17875504
[TBL] [Abstract][Full Text] [Related]
23. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.
Wagner K; Damm F; Göhring G; Görlich K; Heuser M; Schäfer I; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar AA; Fiedler W; Kirchner HH; Brugger W; Zucknick M; Schlegelberger B; Heil G; Ganser A; Krauter J
J Clin Oncol; 2010 May; 28(14):2356-64. PubMed ID: 20368538
[TBL] [Abstract][Full Text] [Related]
24. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.
Goemans BF; Zwaan CM; Miller M; Zimmermann M; Harlow A; Meshinchi S; Loonen AH; Hählen K; Reinhardt D; Creutzig U; Kaspers GJ; Heinrich MC
Leukemia; 2005 Sep; 19(9):1536-42. PubMed ID: 16015387
[TBL] [Abstract][Full Text] [Related]
25. AML: immunophenotypic heterogeneity and prognostic significance of c-kit expression.
Reuss-Borst MA; Bühring HJ; Schmidt H; Müller CA
Leukemia; 1994 Feb; 8(2):258-63. PubMed ID: 7508533
[TBL] [Abstract][Full Text] [Related]
26. Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias.
Paietta E; Ferrando AA; Neuberg D; Bennett JM; Racevskis J; Lazarus H; Dewald G; Rowe JM; Wiernik PH; Tallman MS; Look AT
Blood; 2004 Jul; 104(2):558-60. PubMed ID: 15044257
[TBL] [Abstract][Full Text] [Related]
27. Expression of an abnormal sized c-kit transcript in Hong Kong Chinese acute lymphoblastic leukaemia patients.
Chui CH; Lau FY; Chan AH; Tang JC; Hui CH; Lam CC; Chan LC; Cheng G
Clin Lab Haematol; 1996 Dec; 18(4):261-3. PubMed ID: 9054699
[TBL] [Abstract][Full Text] [Related]
28. Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia.
Park SH; Chi HS; Min SK; Park BG; Jang S; Park CJ
Leuk Res; 2011 Oct; 35(10):1376-83. PubMed ID: 21715005
[TBL] [Abstract][Full Text] [Related]
29. [Clinical significance of CD117/CD34 co-expression in adult patients with acute leukemia].
Shi H; Zhu F; Xiao AQ; Zhang ZR; Zhang R
Ai Zheng; 2006 Jun; 25(6):762-4. PubMed ID: 16764777
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of relapse in acute leukaemia: involvement of p53 mutated subclones in disease progression in acute lymphoblastic leukaemia.
Zhu YM; Foroni L; McQuaker IG; Papaioannou M; Haynes A; Russell HH
Br J Cancer; 1999 Mar; 79(7-8):1151-7. PubMed ID: 10098750
[TBL] [Abstract][Full Text] [Related]
31. Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia.
Tan Y; Liu Z; Wang W; Zhu G; Guo J; Chen X; Zheng C; Xu Z; Chang J; Ren F; Wang H
Leuk Res; 2018 Jun; 69():89-93. PubMed ID: 29705537
[TBL] [Abstract][Full Text] [Related]
32. Identification of new markers discriminating between myeloid and lymphoid acute leukemia.
Haouas H; Haouas S; Uzan G; Hafsia A
Hematology; 2010 Aug; 15(4):193-203. PubMed ID: 20670477
[TBL] [Abstract][Full Text] [Related]
33. A new D816 c-KIT gene mutation in refractory AML1-ETO leukemia.
Lasa A; Carricondo MT; Carnicer MJ; Perea G; Aventín A; Nomdedeu JF
Haematologica; 2006 Sep; 91(9):1283-4. PubMed ID: 16956837
[TBL] [Abstract][Full Text] [Related]
34. AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2.
Jiao B; Wu CF; Liang Y; Chen HM; Xiong SM; Chen B; Shi JY; Wang YY; Wang JH; Chen Y; Li JM; Gu LJ; Tang JY; Shen ZX; Gu BW; Zhao WL; Chen Z; Chen SJ
Leukemia; 2009 Sep; 23(9):1598-604. PubMed ID: 19458628
[TBL] [Abstract][Full Text] [Related]
35. KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia.
Chen X; Dou H; Wang X; Huang Y; Lu L; Bin J; Su Y; Zou L; Yu J; Bao L
Leuk Lymphoma; 2018 Apr; 59(4):829-836. PubMed ID: 28792268
[TBL] [Abstract][Full Text] [Related]
36. Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia.
Jang W; Yoon JH; Park J; Lee GD; Kim J; Kwon A; Choi H; Han K; Nahm CH; Kim HJ; Min WS; Kim M; Kim Y
Blood Cancer J; 2016 Jan; 6(1):e387. PubMed ID: 26771813
[TBL] [Abstract][Full Text] [Related]
37. FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657.
Goemans BF; Zwaan CM; Cloos J; de Lange D; Loonen AH; Reinhardt D; Hählen K; Gibson BE; Creutzig U; Kaspers GJ
Leuk Res; 2010 Oct; 34(10):1302-7. PubMed ID: 20435347
[TBL] [Abstract][Full Text] [Related]
38. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations.
Pullarkat VA; Bueso-Ramos C; Lai R; Kroft S; Wilson CS; Pullarkat ST; Bu X; Thein M; Lee M; Brynes RK
Am J Hematol; 2003 May; 73(1):12-7. PubMed ID: 12701114
[TBL] [Abstract][Full Text] [Related]
39. Systemic mastocytosis associated with t(8;21) acute myeloid leukemia in a child: detection of the D816A mutation of KIT.
Yabe M; Masukawa A; Kato S; Yabe H; Nakamura N; Matsushita H
Pediatr Blood Cancer; 2012 Dec; 59(7):1313-6. PubMed ID: 22847983
[TBL] [Abstract][Full Text] [Related]
40. Transitory dasatinib-resistant states in KIT(mut) t(8;21) acute myeloid leukemia cells correlate with altered KIT expression.
Herrmann MD; Lennerz JK; Bullinger L; Bartholomae S; Holzmann K; Westhoff MA; Corbacioglu S; Debatin KM
Exp Hematol; 2014 Feb; 42(2):90-100. PubMed ID: 24211243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
